Cargando…

The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson’s Disease

Parkinson’s disease (PD) is a chronic neurodegenerative disorder associated with dopamine neuron loss and motor dysfunction. Neuroprotective agents that prevent dopamine neuron death hold great promise for slowing the disease’s progression. The activation of cannabinoid (CB) receptors has shown neur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Hao, Liu, Xiaojie, Chen, Bixuan, Vickstrom, Casey R., Friedman, Vladislav, Kelly, Thomas J., Bai, Xiaowen, Zhao, Li, Hillard, Cecilia J., Liu, Qing-Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700250/ https://www.ncbi.nlm.nih.gov/pubmed/34944056 http://dx.doi.org/10.3390/cells10123548

Ejemplares similares

CB2 Agonist GW842166x Protected against 6-OHDA-Induced Anxiogenic- and Depressive-Related Behaviors in Mice
por: Liu, Xiaojie, et al.
Publicado: (2022)

Epac2 in midbrain dopamine neurons contributes to cocaine reinforcement via enhancement of dopamine release
por: Liu, Xiaojie, et al.
Publicado: (2022)

Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I, et al.
Publicado: (2015)

Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA
por: Tu, Li, et al.
Publicado: (2019)

Cannabinoid receptor subtype 2 (CB(2)R) agonist, GW405833 reduces agonist-induced Ca(2+) oscillations in mouse pancreatic acinar cells
por: Huang, Zebing, et al.
Publicado: (2016)

Erratum to: Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I., et al.
Publicado: (2015)

Erratum to “Inhibition of Endoplasmic Reticulum Stress is Involved in the Neuroprotective Effect of bFGF in the 6-OHDA-Induced Parkinson’s Disease Model”
por: Cai, Pingtao, et al.
Publicado: (2023)

The Neuro-Protective Effects of the TSPO Ligands CB86 and CB204 on 6-OHDA-Induced PC12 Cell Death as an In Vitro Model for Parkinson’s Disease
por: Monga, Sheelu, et al.
Publicado: (2021)

Neuroprotective activity of Stereospermum suaveolens DC against 6-OHDA induced Parkinson's disease model
por: Shalavadi, M. H., et al.
Publicado: (2012)

The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats
por: Song, Lu, et al.
Publicado: (2014)

Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease
por: Voronin, Mikhail V., et al.
Publicado: (2019)

Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist
por: Polini, Beatrice, et al.
Publicado: (2020)

Astrocytic Expression of GSTA4 Is Associated to Dopaminergic Neuroprotection in a Rat 6-OHDA Model of Parkinson’s Disease
por: Jewett, Michael, et al.
Publicado: (2017)

Neuroprotective effects of kukoamine A on 6-OHDA-induced Parkinson's model through apoptosis and iron accumulation inhibition
por: Li, Xin, et al.
Publicado: (2020)

Agathobaculum butyriciproducens Shows Neuroprotective Effects in a 6-OHDA-Induced Mouse Model of Parkinson’s Disease
por: Lee, Da Woon, et al.
Publicado: (2022)

Tetrahydroxystilbene Glucoside Produces Neuroprotection against 6-OHDA-Induced Dopamine Neurotoxicity
por: Huang, Chun, et al.
Publicado: (2018)

PPAR-γ Agonist GW1929 But Not Antagonist GW9662 Reduces TBBPA-Induced Neurotoxicity in Primary Neocortical Cells
por: Wojtowicz, Anna K., et al.
Publicado: (2013)

Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons
por: Ji Yuan, Wen, et al.
Publicado: (2008)

Propolis as a Potential Disease-Modifying Strategy in Parkinson’s disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model
por: C. Gonçalves, Valeria, et al.
Publicado: (2020)

Neuroprotective Effect of Optimized Yinxieling Formula in 6-OHDA-Induced Chronic Model of Parkinson's Disease through the Inflammation Pathway
por: Wei, Renrong, et al.
Publicado: (2019)

Role of endocannabinoid signaling in a septohabenular pathway in the regulation of anxiety- and depressive-like behavior
por: Vickstrom, Casey R., et al.
Publicado: (2020)

Nrf2 Signaling Contributes to the Neuroprotective Effects of Urate against 6-OHDA Toxicity
por: Zhang, Ning, et al.
Publicado: (2014)

Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties
por: Ximenes, José Christian Machado, et al.
Publicado: (2015)

Galangin Exhibits Neuroprotective Effects in 6-OHDA-Induced Models of Parkinson’s Disease via the Nrf2/Keap1 Pathway
por: Chen, Qiu-Xu, et al.
Publicado: (2022)

Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals
por: Niu, Ho-Shan, et al.
Publicado: (2015)

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats
por: Wang, Jie-ping, et al.
Publicado: (2022)

GPR120 Agonist GW9508 Ameliorated Cellular Senescence Induced by ox-LDL
por: Liu, Ruijie, et al.
Publicado: (2020)

Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson's Disease
por: Neves, Kelly Rose Tavares, et al.
Publicado: (2015)

Neuroprotective Effect of Bergamot Juice in 6-OHDA-Induced SH-SY5Y Cell Death, an In Vitro Model of Parkinson’s Disease
por: Ferlazzo, Nadia, et al.
Publicado: (2020)

The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone‐Induced Central Nervous System Demyelination
por: Tomas‐Roig, Jordi, et al.
Publicado: (2016)

GW Stewart
por: Kilmer, Misha E, et al.
Publicado: (2010)

Neuroprotective Properties of Bis-Sulfonamide Derivatives Against 6-OHDA-Induced Parkinson's Model via Sirtuin 1 Activity and in silico Pharmacokinetic Properties
por: Apiraksattayakul, Setthawut, et al.
Publicado: (2022)

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
por: Lu, Lu, et al.
Publicado: (2023)

Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone
por: Rodrigues, Laís D., et al.
Publicado: (2019)

Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson’s Disease
por: Barata-Antunes, Sandra, et al.
Publicado: (2020)

Neuroprotective Effect of 1,4-Naphthoquinones in an In Vitro Model of Paraquat and 6-OHDA-Induced Neurotoxicity
por: Menchinskaya, Ekaterina, et al.
Publicado: (2021)

Editorial: Therapeutic potential of the cannabinoid CB2 receptor
por: Smoum, Reem, et al.
Publicado: (2022)

A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of (6-OHDA)-induced Parkinsonism of rats
por: Choudhury, Mohammed Emamussalehin, et al.
Publicado: (2011)

mGluR5, CB1 and neuroprotection
por: Carvalho, Toniana G., et al.
Publicado: (2016)

Time-Dependent Protection of CB2 Receptor Agonist in Stroke
por: Yu, Seong-Jin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cflh50krtsvifepagicheru49l